A biofoundry is the synthetic biology equivalent of a semiconductor fab — a capital-intensive facility built for high-throughput, automated biological engineering. Biofoundries use liquid-handling robots, automated DNA assembly systems, colony pickers, analytical instruments, and machine learning to cycle through thousands of genetic designs in parallel. This industrialized approach replaces the traditional model of a graduate student manually testing one design at a time with a scalable pipeline that can evaluate tens of thousands of variants per week.
Ginkgo Bioworks operates the world's largest commercial biofoundry, processing millions of engineered organism designs per year for clients across pharmaceuticals, agriculture, food, and industrial chemicals. Academic biofoundries, such as those funded by the U.S. Department of Energy (the Agile BioFoundry) and the UK's SynbiCITE, provide open-access platforms for research and government programs. Amyris, Zymergen, and Twist Bioscience have also built significant biofoundry capabilities.
The biofoundry model is transforming the economics and pace of biological engineering. By standardizing and automating the design-build-test cycle, biofoundries reduce the time and cost of engineering a microorganism from years to months or even weeks. The integration of machine learning to guide design choices — predicting which genetic modifications will improve performance before building them — is further accelerating the cycle. As more biological design data accumulates, biofoundries are becoming increasingly powerful platforms for creating the engineered organisms that underpin the bioeconomy. For deeper coverage, see SynBioIntel.